arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ARS Pharmaceuticals, Inc.

SPRY
$2.62 ▼ -0.43 (-14.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

ARS Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $260.2M
Dividend Yield —
Revenue Growth 114.2% ↘
Op. Margin -182.6% ↗
ROIC -44.5% ↘
FCF / Share $-0.61 ↘
Trailing P/E —
Price / Book 20.8x
FCF Yield —
Debt / Equity 7.73
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$33.66M
↑ +114.2% —
Net Income Profit after all expenses
$-62.34M
↓ -38.9% —
Operating Margin Operating profit as % of sales
-182.6%
↑ +31.1% 0th
FCF / Share Free cash flow per share
$-0.61
↓ -35.5% —
Long-Term Debt Long-term obligations
$96.68M
— +0.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns
5
Financial Health ↑
24
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters